Santen and RemeGen sign licence deal for retinal disease injection
Santen Pharmaceutical has signed a licensing agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein designed to…
Ophthalmology
-
-
Boehringer Ingelheim marks retinal disease push with $327m licensing deal
Boehringer Ingelheim currently does not have any approved therapies for ophthalmic indications, but the company is looking to change that…
-
Amphastar and Anji make licence agreement for three new peptides
Amphastar Pharmaceuticals has signed an exclusive licence agreement with Nanjing Anji Biotechnology, focusing on the development, production, use and commercialisation…
-
Viridian and Kissei to advance veligrotug and VRDN-003 in Japan
Viridian Therapeutics and Kissei Pharmaceutical have signed an exclusive partnership and licence agreement for advancing veligrotug and subcutaneous VRDN-003, potential…
-
Re-Vana Therapeutics and Boehringer Ingelheim collaborate for eye therapies
Re-Vana Therapeutics, a spin-out from Queen’s University, has entered a partnership and licence agreement with Boehringer Ingelheim for the development…
-
Torrent Pharmaceuticals to acquire stake in JB Pharma for $3bn
Torrent Pharmaceuticals, headquartered in Gujerat, India, has signed definitive agreements for the acquisition of a controlling stake in JB Chemicals…
-
Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in
Alvotech has moved one step closer to entering the Eylea (aflibercept 2 mg) biosimilar market, after a European Medicines Agency…
-
Bayer’s Eylea set for longer treatment intervals to challenge Roche’s Vabysmo
Bayer’s retinal disease treatment Eylea (aflibercept) is set for an extended treatment interval, a label extension that could give the…
-
Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge
The European Medicines Agency (EMA) has approved Roche’s Vabysmo (faricimab) in single-dose prefilled syringe form for three retinal conditions that…
-
Formosa and Medvisis agree on post-operative eye pain therapy
Formosa Pharmaceuticals in Taiwan has signed an exclusive licensing agreement with Medvisis Switzerland to commercialise clobetasol propionate ophthalmic suspension, 0.05%…
